News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CLL Pharma and Leurquin-Mediolanum Announce Initiation of Phase 1b Clinical Trial of the Compound Syn1002 in Pain


7/2/2013 2:24:59 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CLL Pharma and Leurquin-Mediolanum announced today that enrollment has begun in a Phase 1b clinical trial of Syn1002 to demonstrate its proof of concept in validated human pain models.

This study follows the completion of the Phase 1 single dose-escalation study of Syn1002 which showed that the compound is very well tolerated in healthy volunteers. Syn1002 is a lead drug candidate, which has shown efficacy in various animal models of inflammatory and neuropathic pain and also in preclinical models of arthritis and Crohn’s disease.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES